Cytokinetics (CYTK) Long-Term Investments (2016 - 2025)
Historic Long-Term Investments for Cytokinetics (CYTK) over the last 13 years, with Q3 2024 value amounting to $269.2 million.
- Cytokinetics' Long-Term Investments rose 164016.03% to $269.2 million in Q3 2024 from the same period last year, while for Sep 2024 it was $269.2 million, marking a year-over-year increase of 164016.03%. This contributed to the annual value of $40.5 million for FY2023, which is 1321.83% down from last year.
- Per Cytokinetics' latest filing, its Long-Term Investments stood at $269.2 million for Q3 2024, which was up 164016.03% from $305.4 million recorded in Q2 2024.
- In the past 5 years, Cytokinetics' Long-Term Investments registered a high of $305.4 million during Q2 2024, and its lowest value of $10.7 million during Q2 2022.
- Its 5-year average for Long-Term Investments is $79.0 million, with a median of $40.5 million in 2023.
- In the last 5 years, Cytokinetics' Long-Term Investments crashed by 8551.96% in 2022 and then surged by 164016.03% in 2024.
- Cytokinetics' Long-Term Investments (Quarter) stood at $37.0 million in 2020, then surged by 311.46% to $152.0 million in 2021, then crashed by 69.28% to $46.7 million in 2022, then dropped by 13.22% to $40.5 million in 2023, then surged by 564.05% to $269.2 million in 2024.
- Its last three reported values are $269.2 million in Q3 2024, $305.4 million for Q2 2024, and $15.4 million during Q1 2024.